The increased secretion of glucagon-like peptide-1 (GLP-1) after Roux-en-Y gastric bypass (RYGB) is regarded as the main reason for the improvement of blood glucose. However, the single-nucleotide polymorphisms (SNPs) of GLP-1 Receptor (GLP1R) impair receptor function, subsequently affecting β cell insulin secretion function, ultimately affecting the efficacy of RYGB. In this study, we revealed that two SNPs in GLP1R gene, rs3765467 and rs10305492, could significantly reduce the insulin secreted by β cells and the cyclic AMP concentration, whereas promote β cell apoptosis. Under high glucose exposure, rs3765467 and rs10305492 impaired β cell secretion of insulin and β cell viability in the same way; in other words, GLP1R rs3765467 and rs10305492 exert an effect on pancreatic β cell glucose-stimulated insulin secretion. Moreover, GLP-1 antagonist Exendin (9-39) further enhanced, whereas GLP-1 agonist Exendin-4 partially attenuated the effects of SNPs on the functions and apoptosis of β cells. In conclusion, the rs3765467 and rs10305492 SNPs in GLP1R show to exert a critical effect on regulating insulin secretory capacity of β cells and β cell mass. Through leading to the dysfunction and apoptosis of β cells, GLP1R rs3765467 and rs10305492 might also impair GLP-1 interaction with GLP1R, therefore attenuating the therapeutic effect of RYGB.
Get full access to this article
View all access options for this article.
References
1.
Al-MajedH.T., JonesP.M., PersaudS.J., SugdenD., HuangG.C., AmielS., et al. (2004). ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. J Endocrinol, 180, 155–166.
2.
AndersonS.L., TrujilloJ.M., McDermottM., and SaseenJ.J. (2012). Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003), 52, 466–471.
3.
BaggioL.L., and DruckerD.J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131–2157.
4.
BeinbornM., WorrallC.I., Mc BrideE.W., and KopinA.S. (2005). A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept, 130, 1–6.
5.
BrubakerP.L., and DruckerD.J. (2004). Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology, 145, 2653–2659.
6.
ButlerA.E., JansonJ., Bonner-WeirS., RitzelR., RizzaR.A., and ButlerP.C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 52, 102–110.
7.
ChenL., MaglianoD.J., and ZimmetP.Z. (2011). The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol, 8, 228–236.
8.
CozacovY., RoyM., MoonS., MarinP., Lo MenzoE., SzomsteinS., et al. (2014). Mid-term results of laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass in adolescent patients. Obes Surg, 24, 747–752.
9.
DayJ.W., LiP., PattersonJ.T., ChabenneJ., ChabenneM.D., GelfanovV.M., et al. (2011). Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J Pept Sci, 17, 218–225.
10.
DoyleM.E., and EganJ.M. (2007). Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther, 113, 546–593.
11.
FortinJ.P., SchroederJ.C., ZhuY., BeinbornM., and KopinA.S. (2010). Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther, 332, 274–280.
12.
FujimotoK., ChenY., PolonskyK.S., and DornG.W., II (2010). Targeting cyclophilin D and the mitochondrial permeability transition enhances beta-cell survival and prevents diabetes in Pdx1 deficiency. Proc Natl Acad Sci U S A, 107, 10214–10219.
13.
HanE., ParkH.S., KwonO., ChoeE.Y., WangH.J., LeeY.H., et al. (2016). A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes. Medicine (Baltimore) 95,e5155.
14.
HeitJ.J., KarnikS.K., and KimS.K. (2006). Intrinsic regulators of pancreatic beta-cell proliferation. Annu Rev Cell Dev Biol, 22, 311–338.
15.
HuangL., HuC., CaoH., WuX., WangR., LuH., et al. (2018). MicroRNA-29c increases the chemosensitivity of pancreatic cancer cells by inhibiting USP22 mediated autophagy. Cell Physiol Biochem, 47, 747–758.
16.
JavorskyM., GotthardovaI., KlimcakovaL., KvapilM., ZidzikJ., SchronerZ., et al. (2016). A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins. Diabetes Obes Metab, 18, 941–944.
17.
JensterleM., PirsB., GoricarK., DolzanV., and JanezA. (2015). Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol, 71, 817–824.
18.
KooleC., WoottenD., SimmsJ., ValantC., MillerL.J., ChristopoulosA., et al. (2011). Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol, 80, 486–497.
19.
LecompteS., PasquettiG., HermantX., Grenier-BoleyB., Gonzalez-GrossM., De HenauwS., et al. (2013). Genetic and molecular insights into the role of PROX1 in glucose metabolism. Diabetes, 62, 1738–1745.
20.
LinC.H., LeeY.S., HuangY.Y., HsiehS.H., ChenZ.S., and TsaiC.N. (2015). Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes. J Diabetes Res 2015,176949.
21.
LiuY., ZhouY., WangY., GengD., and LiuJ. (2011). Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1. Obes Surg, 21, 1424–1431.
22.
McKennaD., SelzerD., BurchettM., ChoiJ., and MattarS.G. (2014). Revisional bariatric surgery is more effective for improving obesity-related co-morbidities than it is for reinducing major weight loss. Surg Obes Relat Dis, 10, 654–659.
23.
McLaughlinT., PeckM., HolstJ., and DeaconC. (2010). Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab, 95, 1851–1855.
24.
MeierJ.J., HuckingK., HolstJ.J., DeaconC.F., SchmiegelW.H., and NauckM.A. (2001). Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes, 50, 2497–2504.
25.
MurakamiM., MiyashitaK., KakizakiS., SaitoS., YamadaM., IriuchijimaT., et al. (1995). Clinical usefulness of thyroid-stimulating antibody measurement using Chinese hamster ovary cells expressing human thyrotropin receptors. Eur J Endocrinol, 133, 80–86.
26.
Navarrete AulestiaS., LeybaJ., NavarreteL.L.S., Garcia CaballeroM., SanchezN., PulgarV., et al. (2012). Roux-en-Y gastric bypass for treatment of patients with DM type 2 and BMI of 30 to 35 Kg/m(2). Nutr Hosp, 27, 1160–1165.
27.
NguyenK.T., and KornerJ. (2014). The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery. Curr Diab Rep 14,481.
28.
PreitnerF., IbbersonM., FranklinI., BinnertC., PendeM., GjinovciA., et al. (2004). Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest, 113, 635–645.
29.
SathananthanA., ManC.D., MichelettoF., ZinsmeisterA.R., CamilleriM., GieslerP.D., et al. (2010). Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care, 33, 2074–2076.
30.
SchumannD.M., MaedlerK., FranklinI., KonradD., StorlingJ., Boni-SchnetzlerM., et al. (2007). The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci U S A, 104, 2861–2866.
31.
ScottR.A., FreitagD.F., LiL., ChuA.Y., SurendranP., YoungR., et al. (2016). A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci Transl Med 8,341ra76.
32.
TokuyamaY., MatsuiK., EgashiraT., NozakiO., IshizukaT., and KanatsukaA. (2004). Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract, 66, 63–69.
33.
VilsbollT., KrarupT., DeaconC.F., MadsbadS., and HolstJ.J. (2001). Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 50, 609–613.
34.
WangJ., KilicG., AydinM., BurkeZ., OliverG., and Sosa-PinedaB. (2005). Prox1 activity controls pancreas morphogenesis and participates in the production of “secondary transition”. pancreatic endocrine cells. Dev Biol, 286, 182–194.
35.
WeinsteinL.S., YuS., WarnerD.R., and LiuJ. (2001). Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev, 22, 675–705.
36.
WeirG. C., and Bonner-WeirS. (2004). Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53 Suppl, 3, S16–S21.
37.
WesselJ., ChuA.Y., WillemsS.M., WangS., YaghootkarH., BrodyJ.A., et al. (2015). Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun 6,5897.
38.
XiongX., SunX., WangQ., QianX., ZhangY., PanX., et al. (2016). SIRT6 protects against palmitate-induced pancreatic beta-cell dysfunction and apoptosis. J Endocrinol, 231, 159–165.
39.
YuM., WangK., LiuH., and CaoR. (2019). GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients. Pharmacogenomics, 20, 273–277.
40.
ZhuL., MoZ., YangX., LiuS., WangG., LiP., et al. (2012). Effect of laparoscopic Roux-en-Y gastroenterostomy with BMI <35 kg/m(2) in type 2 diabetes mellitus. Obes Surg, 22, 1562–1567.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
